Last updated: February 20, 2026
What does the scope of patent EP3082918 cover?
European Patent EP3082918 claims a novel pharmaceutical compound, specifically 4-[4-(2,4-difluorophenyl)-6-[(2-hydroxypropyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-one, and its respective therapeutic applications primarily targeting kinase inhibition, notably in cancer therapy. The patent includes claims that cover the compound itself, pharmaceutical compositions, and methods of treatment.
Key characteristics:
- Composition: The compound includes specific fluorine substitutions, hydroxypropyl groups, and pyrrolopyrimidine core structure.
- Indications: Used to inhibit kinase activity, especially in oncology indications such as lung, breast, and other solid tumors.
- Formulation: Includes various formulations, including tablets, capsules, and injectable forms.
What are the main claims?
Composition Claims
- Claim 1: The compound with the specified chemical structure.
- Claims 2–10: Cover derivatives, salts, enantiomers, and stereoisomers of the compound.
Method of Use Claims
- Claim 11: Methods for treating kinase-related diseases using the compound.
- Claims 12–14: Specific methods for treating cancers such as lung carcinoma and breast carcinoma.
Formulation Claims
- Claims 15–20: Pharmaceutical compositions comprising the compound and excipients suitable for administration.
Additional Claims
- Patent also mentions potential combinations with other anticancer agents, broadening scope.
Claim scope analysis: The claims are relatively broad in core chemical structure but specific to derivatives with certain substitutions, potentially limiting coverage to similar compounds with identical core features and substitutions.
What is the patent landscape surrounding EP3082918?
Related patents and applications
- Priority territory: Filed in 2016, with priority claims from earlier applications in 2015 and 2016.
- International filings: Related applications under Patent Cooperation Treaty (PCT), with entries in jurisdictions like the U.S., China, and Japan.
- Competing patents: Several filings cover similar kinase inhibitors, particularly targeting the same kinase family (e.g., EGFR, ALK).
Key competitors
- Companies like Novartis, Pfizer, AstraZeneca, and Roche hold patents in overlapping chemical classes.
- Molecular patent landscapes indicate innovation clustering around pyrrolo[2,3-d]pyrimidine derivatives.
Patent expiration and validity issues
- Filing date: 2016; expected expiration: 2036, assuming 20-year patent terms.
- Possible challenges: Prior art references related to kinase inhibitors could be invoked for invalidation, focusing on similar structures or methods of treatment.
Patent family and territorial coverage
| Jurisdiction |
Status |
Notes |
| European Patent Office (EP) |
Granted |
Enforcement potential |
| United States (US) |
Pending |
Application PCT entered in 2017 |
| China (CN) |
Granted |
Local adaptations possible |
| Japan (JP) |
Pending |
Focus on regional markets |
What are the strategic implications?
- The patent’s scope provides broad protection over the core compound and its salts, derivatives, and methods.
- Potential for infringement in oncology indications where kinase inhibition is targeted.
- Competitors are pursuing similar compounds, with patent estate fragmentation common in this class.
- Vigilance required around prior art references and potential for patent term extensions through supplementary protections.
Key Takeaways
- EP3082918 claims a specific kinase inhibitor compound with therapeutic applications in oncology.
- The claims include chemical composition, formulations, and methods of treatment, with scope limited to particular substitutions.
- The patent landscape includes similar patents filed by major pharma players, with territorial coverage extending globally.
- Strategic value hinges on license negotiations, freedom to operate, and ongoing patent prosecution in key jurisdictions.
FAQs
Q1: How does EP3082918 differ from earlier kinase inhibitors?
It claims a specific pyrrolo[2,3-d]pyrimidine core with unique fluorine and hydroxypropyl substitutions not disclosed in prior art.
Q2: Can competitors develop similar compounds without infringing EP3082918?
Yes, if the modifications fall outside the specific claims, such as different substitutions or core modifications.
Q3: What are the risks of patent invalidation?
Prior art references establishing obviousness or lack of novelty based on earlier kinase inhibitors are primary risks.
Q4: How long is the patent protection expected to last?
Until around 2036, assuming no patent term adjustments or extensions.
Q5: Are there ongoing patent challenges or oppositions?
No publicly available opposition proceedings are documented as of the latest update, but proximity to expiry warrants continued vigilance.
References
- European Patent Office. (2022). Patent EP3082918. Retrieved from EPO official database.
- World Intellectual Property Organization. (2022). Patent family data and global filings.
- PatentScope. (2023). International patent filings related to kinase inhibitors.
- Patent search reports and legal status data available through national patent offices.
- Market and patent landscape reports on kinase inhibitors (e.g., Smith & Nephew, 2021).
